For renal cancer, He et al. [18] investigated the ability of preoperative serum albumin (ALB) to globulin (GLB) ratio (AGR), which predicts the long-term mortality of RCC patients, and proved AGR is an inexpensive survival predictor to be considered for routine clinical use. This evidence concerns the gene ALB and renal carcinoma.